Covid inquiry: Failure to consider ‘potentially massive impact’ of lockdown pre-pandemic
The UK may not have been well prepared “at all”, says the lead lawyer for the Covid inquiry.
Similar Posts
Company faces lawsuit over lead-tainted applesauce
Company faces lawsuit over lead-tainted applesauce – CBS News Watch CBS News Wanabana, one of the companies that has recalled applesauce pouches due to lead contamination, is facing a possible class action lawsuit over the tainted products. Meg Oliver reports. Be the first to know Get browser notifications for breaking news, live events, and exclusive…
Should we be worried about Covid this winter?
Experts are not too concerned about a new variant of Covid but say monitoring should continue.
MoonLake Immunotherapeutics explores sale | Reuters News Agency
Business & FinanceDealsHealth 14 July 2023, 5:43 pm 1 minute MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition. Market Impact MoonLake’s shares ended trading up 8.4% at $54.27 on the news on Friday,…
As COVID cases rise, probiotics could reduce symptoms and infection, study suggests
For those who aren’t vaccinated against COVID-19, probiotics could offer a level of protection against the virus, a new study suggests. In a randomized, placebo-controlled study led by Duke Health in North Carolina, probiotics were shown to have a “significant ability to delay a COVID infection and reduce symptoms” among people who had not been…
Narcan, The Lifesaving Drug That Can Reverse An Opioid Overdose, Can Be Bought Over The Counter Soon
The Food and Drug Administration has approved Narcan, a naloxone nasal spray that can reverse opioid overdoses and save lives, for over-the-counter use. In an announcement Wednesday, FDA Commissioner Robert M. Califf said the move is meant to address a “dire public health need” and will help increase access and reduce opioid overdose deaths in…
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers’ drug pipeline after…
